Hong Wan

Company: Tallac Therapeutics

Job title: President, Chief Executive Officer & Co-Founder

Seminars:

TAC-001: A Toll-Like 9 Receptor Immune Agonist Conjugate for Solid Tumors 2:00 pm

Reviewing the scientific rationale behind TAC-001, a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22 Outlining the ongoing TAC-001 phase ½ clinical trial for advanced or metastatic solid tumors Exploring the potential of Tallac’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform for systemically administered immune agonist conjugatesRead more

day: Day Two